GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (OSTO:ENZY) » Definitions » Debt-to-Equity

Enzymatica AB (OSTO:ENZY) Debt-to-Equity : 0.01 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Enzymatica AB Debt-to-Equity?

Enzymatica AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr1.14 Mil. Enzymatica AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Enzymatica AB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was kr157.96 Mil. Enzymatica AB's debt to equity for the quarter that ended in Mar. 2025 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Enzymatica AB's Debt-to-Equity or its related term are showing as below:

OSTO:ENZY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.09   Max: 1.42
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Enzymatica AB was 1.42. The lowest was 0.01. And the median was 0.09.

OSTO:ENZY's Debt-to-Equity is ranked better than
99.88% of 813 companies
in the Drug Manufacturers industry
Industry Median: 0.26 vs OSTO:ENZY: 0.01

Enzymatica AB Debt-to-Equity Historical Data

The historical data trend for Enzymatica AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymatica AB Debt-to-Equity Chart

Enzymatica AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.02 0.18 0.24 0.01

Enzymatica AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.39 0.01 0.01 0.01

Competitive Comparison of Enzymatica AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzymatica AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Enzymatica AB's Debt-to-Equity falls into.


;
;

Enzymatica AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Enzymatica AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Enzymatica AB's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzymatica AB  (OSTO:ENZY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Enzymatica AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Enzymatica AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzymatica AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB Headlines

From GuruFocus

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson 12-07-2015